共 13 条
[1]
Jounsuu H., Eriksson M., Hatrmann J., Et al., Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO), Proceed. Am Soc Clin Oncol, Abstr. LBA, 1, (2011)
[2]
Pruthi S., Qin R., Terstriep S.A., Et al., The evaluation of flaxseed for hot flashes, results of a randomized, controlled trial, NCCTG study N08C7, Proceed. Am Soc Clin Oncol Abstr. CRA, 9015, (2011)
[3]
Paz-Ares L.G., De Marinis F., Dediu M., Et al., PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC), Proceed. Am Soc Clin Oncol, Abstr. CRA, 7510, (2011)
[4]
Larsen E.C., Salzer W.L., Devidas M., Et al., Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232, Proceed. Am Soc Clin Oncol, Abstr., 3, (2011)
[5]
Whelan T.J., Olivotto I., Ackerman I., Et al., NCIC-CTG MA.20: An Intergroup Trial of Regional Nodal Irradiation in Early Breast Cancer, Proceed. Am Soc Clin Oncol, Abstr. LBA, 1003, (2011)
[6]
Chapman P.B., Hauschild A., Robert C., Et al., Phase III randomized, open-label, multicenter trail (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma, Proceed. Am Soc Clin Oncol, Abstr. LBA, 4, (2011)
[7]
Rini B.I., Et al., Axatinib versus Sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial, Proceed. Am Soc Clin Oncol, Abstr., 4503, (2011)
[8]
Kris M.G., Johnson B.E., Kwiatkowski D.J., Et al., Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI's lung cancer mutation consortium (LCMC), Proceed. Am Soc Clin Oncol, Abstr. CRA, 7506, (2011)
[9]
Tsimberidou A.M., Iskander N.G., Hong D.S., Et al., Personalized medicine in a phase i clinical trials program: The M.D. Anderson Cancer Center initiative, Proceed. Am Soc Clin Oncol, Abstr. CRA, 2500, (2011)
[10]
Scher H.I., Heller G., Molina A., Et al., Evaluating of circulating tumor cell (CTCs) enumeration as an efficacy response biomarker of survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel, Proceed. Am Soc Clin Oncol, Abstr. CRA, 2500, (2011)